-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

It's All In The Genes: What Hodgkin Lymphoma Teaches Us About Checkpoint Blockade

Program: Spotlight Sessions
Session: Checkpoint Blockade: Defining A New Treatment Paradigm in Hodgkin Lymphoma and Allogeneic Transplantation
Sunday, December 6, 2020, 11:55 AM-12:00 PM

Margaret A. Shipp, MD

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Disclosures: Shipp: Bristol Myers Squibb: Consultancy, Research Funding; Ono Pharmaceutical: Honoraria; Bayer: Honoraria; Merck: Research Funding; Celgene: Honoraria.

OffLabel Disclosure: PD-1 blocking antibodies

See more of: Checkpoint Blockade: Defining A New Treatment Paradigm in Hodgkin Lymphoma and Allogeneic Transplantation
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>